New Approaches to the Clinical Challenges of Tardive Dyskinesia
neuroscienceCME WebcastPremiere Date: Friday, March 9, 2018
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, March 9, 2019
Note: Credit Is No Longer Available
|Stephen R. Marder, MD
Daniel X. Freedman Professor of Psychiatry
Vice Chair for Education
Semel Institute for Neuroscience at UCLA
Desert Pacific Mental Illness Research, Education, and Clinical Center
Los Angeles, CA
This video is a replay of a plenary session from the 10th Annual Chair Summit Master Class for Neuroscience Professional Development held in New Orleans, LA on November 16-18, 2017.
At the end of this CE activity, participants should be able to:
- Identify the signs and symptoms of tardive dyskinesia (TD).
- Integrate assessment scales to accurately identify and assess the severity of TD in at least 80% of patients on antipsychotics throughout the course of treatment.
- Individualize treatment selection for patients with TD based on evidence-based data.
This activity is supported by an educational grant from Teva Pharmaceuticals.
Physicians, physician assistants, nurse practitioners, pharmacists, certified case managers, social workers, and other nonphysician healthcare professionals with an interest in psychiatry, neurology, and the neurociences.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest though a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Marder reports that he receives research support from Neurocrine Biosciences, Inc. He is a consultant for Allergan; Lundbeck; Neurocrine Biosciences, Inc.; Newron Pharmaceuticals SPA.; Otsuka America Pharmaceutical, Inc.; Takeda Pharmaceuticals North America, Inc.; and Teva Pharmaceuticals.
Howard Bliwise, MD (peer reviewer) has no disclosures to resport.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Daniela V. DiBiase, MS (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).